74 related articles for article (PubMed ID: 10817062)
1. Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination.
Kibur M; af Geijerstamm V; Pukkala E; Koskela P; Luostarinen T; Paavonen J; Schiller J; Wang Z; Dillner J; Lehtinen M
Sex Transm Infect; 2000 Feb; 76(1):13-7. PubMed ID: 10817062
[TBL] [Abstract][Full Text] [Related]
2. Prospects for phase III-IV HPV vaccination trials in the Nordic countries and in Estonia.
Lehtinen M; Kibur M; Luostarinen T; Anttila A; Pukkala E
J Clin Virol; 2000 Oct; 19(1-2):113-22. PubMed ID: 11091154
[TBL] [Abstract][Full Text] [Related]
3. Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up.
Rana MM; Huhtala H; Apter D; Eriksson T; Luostarinen T; Natunen K; Paavonen J; Pukkala E; Lehtinen M
Int J Cancer; 2013 Jun; 132(12):2833-8. PubMed ID: 23180157
[TBL] [Abstract][Full Text] [Related]
4. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy.
Lehtinen M; Idänpään-Heikkilä I; Lunnas T; Palmroth J; Barr E; Cacciatore R; Isaksson R; Kekki M; Koskela P; Kosunen E; Kuortti M; Lahti L; Liljamo T; Luostarinen T; Apter D; Pukkala E; Paavonen J
Int J STD AIDS; 2006 Apr; 17(4):237-46. PubMed ID: 16595046
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial.
Mao C; Koutsky LA; Ault KA; Wheeler CM; Brown DR; Wiley DJ; Alvarez FB; Bautista OM; Jansen KU; Barr E
Obstet Gynecol; 2006 Jan; 107(1):18-27. PubMed ID: 16394035
[TBL] [Abstract][Full Text] [Related]
6. [Cervical cancer prevention: the impact of HPV vaccination].
Monsonégo J
Gynecol Obstet Fertil; 2006 Mar; 34(3):189-201. PubMed ID: 16529969
[TBL] [Abstract][Full Text] [Related]
7. Prerequisites for human papillomavirus vaccine trial: results of feasibility studies.
Paavonen J; Halttunen M; Hansson BG; Nieminen P; Rostila T; Lehtinen M
J Clin Virol; 2000 Oct; 19(1-2):25-30. PubMed ID: 11091145
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
[TBL] [Abstract][Full Text] [Related]
9. No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11.
Luostarinen T; af Geijersstam V; Bjørge T; Eklund C; Hakama M; Hakulinen T; Jellum E; Koskela P; Paavonen J; Pukkala E; Schiller JT; Thoresen S; Youngman LD; Dillner J; Lehtinen M
Int J Cancer; 1999 Mar; 80(6):818-22. PubMed ID: 10074912
[TBL] [Abstract][Full Text] [Related]
10. [Vaccination against human papillomavirus for the prevention of cervical cancer].
Quint WG; ter Harmsel WA; van Doorn LJ
Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1380-4. PubMed ID: 16841585
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: Results from a longitudinal Dutch cohort study.
Mollers M; King AJ; Knol MJ; Scherpenisse M; Meijer CJ; van der Klis FR; de Melker HE
Vaccine; 2015 May; 33(23):2678-83. PubMed ID: 25887090
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine.
Goldie SJ; Grima D; Kohli M; Wright TC; Weinstein M; Franco E
Int J Cancer; 2003 Oct; 106(6):896-904. PubMed ID: 12918067
[TBL] [Abstract][Full Text] [Related]
13. Joint effect of HPV16 with Chlamydia trachomatis and smoking on risk of cervical cancer: antagonism or misclassification (Nordic countries).
Hakama M; Luostarinen T; Hallmans G; Jellum E; Koskela P; Lehtinen M; Thoresen S; Youngman L; Hakulinen T
Cancer Causes Control; 2000 Oct; 11(9):783-90. PubMed ID: 11075866
[TBL] [Abstract][Full Text] [Related]
14. A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I/IIa Trial.
Hillemanns P; Denecke A; Woelber L; Böhmer G; Jentschke M; Schjetne KW; Bruins Slot KMH; Fredriksen AB
Clin Cancer Res; 2022 Nov; 28(22):4885-4892. PubMed ID: 36129459
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial.
van Driel WJ; Ressing ME; Kenter GG; Brandt RM; Krul EJ; van Rossum AB; Schuuring E; Offringa R; Bauknecht T; Tamm-Hermelink A; van Dam PA; Fleuren GJ; Kast WM; Melief CJ; Trimbos JB
Eur J Cancer; 1999 Jun; 35(6):946-52. PubMed ID: 10533477
[TBL] [Abstract][Full Text] [Related]
16. Cancer Registry follow-up for 17 million person-years of a nationwide maternity cohort.
Lehtinen M; Surcel HM; Natunen K; Pukkala E; Dillner J
Cancer Med; 2017 Dec; 6(12):3060-3064. PubMed ID: 29071810
[TBL] [Abstract][Full Text] [Related]
17. On sample sizes to estimate the protective efficacy of a vaccine.
O'Neill RT
Stat Med; 1988 Dec; 7(12):1279-88. PubMed ID: 3231951
[TBL] [Abstract][Full Text] [Related]
18. Erratum to "HPV16 whole genome minority variants in persistent infections from young Dutch women" [J. Clin. Virol. 119 (2019) 24-30].
Lagström S; van der Weele P; Rounge TB; Christiansen IK; King AJ; Ambur OH
J Clin Virol; 2020 Mar; 124():104286. PubMed ID: 32057648
[No Abstract] [Full Text] [Related]
19. Report of a Case of the Difficulties Met with in Primiparous Women.
Garrett AE
Tex Med J (Austin); 1893 Aug; 9(2):57-60. PubMed ID: 36954664
[No Abstract] [Full Text] [Related]
20. Mass attack on proteins.
Frederickson R
Nat Biotechnol; 1999 Sep; 17(9):840. PubMed ID: 10471966
[No Abstract] [Full Text] [Related]
[Next] [New Search]
